Genetic knockout or pharmacological blockade of ASK1 reduces renal inflammation and fibrosis in unilateral ureteral obstruction (UUO) [7] and CKD [8], which implies that ASK1 is a potential therapeutic target for the treatment of CKD. The gene discussed is MAP3K5; the disease is Ureteral obstruction.